New paper investigating the sample sizes in AD secondary prevention trials

Isadora Lopes Alves and colleagues published a new paper entitled “Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging” in the journal Alzheimer’s Research & Therapy.

This work aimed to determine if and when distribution volume ratio and regional quantitative values could improve statistical power in Alzheimer’s disease (AD) prevention trials. Authors showed that sample sizes in AD secondary prevention trials can be reduced by the acquisition of dynamic PET scans and/or by restricting inclusion to subjects with intermediate amyloid burden or to APOE-ε4 carriers only. Using a targeted early composite only leads to reductions of sample size requirements in primary prevention trials. These findings support strategies to enable smaller Proof-of-Concept Phase II clinical trials to better streamline drug development.

Congratulations to the authors: Isadora Lopes Alves, Fiona Heeman, Lyduine E. Collij, Gemma Salvadó, Nelleke Tolboom, Natàlia Vilor-Tejedor, Pawel Markiewicz, Maqsood Yaqub, David Cash, Elizabeth C. Mormino, Philip S. Insel, Ronald Boellaard, Bart N. M. van Berckel, Adriaan A. Lammertsma, Frederik Barkhof & Juan Domingo Gispert

This open access article can be found here!

New paper investigating the sample sizes in AD secondary prevention trials
More News